proto-oncogene proteins c-met

Preferred Label : proto-oncogene proteins c-met;

MeSH definition : Cell surface protein-tyrosine kinase receptors for HEPATOCYTE GROWTH FACTOR. They consist of an extracellular alpha chain which is disulfide-linked to the transmembrane beta chain. The cytoplasmic portion contains the catalytic domain and sites critical for the regulation of kinase activity. Mutations of the gene for PROTO-ONCOGENE PROTEINS C-MET are associated with papillary renal carcinoma and other neoplasia.; Cell surface protein-tyrosine kinase receptors for HEPATOCYTE GROWTH FACTOR. They consist of an extracellular alpha chain which is disulfide-linked to the transmembrane beta chain. The cytoplasmic portion contains the catalytic domain and sites critical for the regulation of kinase activity. Mutations in the c-met proto-oncogene are associated with papillary renal carcinoma and other neoplasia.;

MeSH synonym : met proto oncogene proteins; receptor, scatter factor; receptor, hgf; receptor, hepatocyte growth factor; hepatocyte growth factor receptor; hgf receptor; scatter factor receptor; c-met proteins; c met proteins; met proto-oncogene proteins; proto-oncogene proteins, met; proto oncogene proteins c met; MET Receptor Tyrosine Kinase; c-Met Receptor Tyrosine Kinase; c Met Receptor Tyrosine Kinase; MET Proto-Oncogene, Receptor Tyrosine Kinase; MET Proto Oncogene, Receptor Tyrosine Kinase;

CISMeF synonym : EC 2.7.1.112;

Registry Number MeSH : EC 2.7.10.1;

MeSH annotation : DF: C MET PROTEINS;

Is substance : O;

UNII : EC 2.7.10.1;

Détails

Origin ID

D019859;

UMLS CUI

C0072453;

Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- biosynthesis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- deficiency [MeSH Qualifier]
- drug effects [MeSH Qualifier]
- economics [MeSH Qualifier]
- genetics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- physiology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- ultrastructure [MeSH Qualifier]
- urine [MeSH Qualifier]
CISMeF manual mappings
- c-Met Inhibitor [NCIt concept]
Indexing information
- ARQ 197 [MeSH Supplementary Concept]
- EMD1214063 [MeSH Supplementary Concept]
- N-(4-((2-((cyclopropylcarbonyl)amino)imidazo(1,2-a)pyridin-6-yl)oxy)-3-fluorophenyl)-6-methyl-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide [MeSH Supplementary Concept]
Record concept(s)
- Proto-Oncogene proteins c-met [MeSH concept]
Related MeSH Supplementary Concept(s)
- HGFR protein, mouse [MeSH Supplementary Concept]
- MET protein, human [MeSH Supplementary Concept]
See also (suggested by CISMeF)
- onartuzumab [MeSH Supplementary Concept]
See also inter- (CISMeF)
- MET Positive [NCIt concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Enzyme [UMLS semantic type]
- Receptor [UMLS semantic type]
UMLS correspondences (same concept)
- Hepatocyte growth factor receptor [LOINC component]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients